Byrne Asset Management LLC Prothena Corp Public LTD CO Transaction History

Byrne Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Jan 29, 2025	BUY	$16.73 - $24.79 $12,714 - $18,840	760 New	760 $12,000
Q3 2024 Jan 28, 2025	BUY	$16.73 - $24.79 $12,714 - $18,840	760 New	760 $12,000
Q2 2024 Jul 23, 2024	BUY	$19.54 - $26.15 $781 - $1,046	40 Added 5.88%	720 $14,000
Q1 2024 Apr 22, 2024	BUY	$24.75 - $40.66 $9,405 - $15,450	380 Added 126.67%	680 $16,000
Q4 2023 Jan 29, 2024	BUY	$32.31 - $52.32 $646 - $1,046	20 Added 7.14%	300 $10,000
Q3 2023 Oct 31, 2023	BUY	$47.3 - $70.6 $946 - $1,412	20 Added 7.69%	280 $13,000
Q2 2023 Jul 21, 2023	SELL	$48.26 - $78.59 $2,895 - $4,715	-60 Reduced 18.75%	260 $17,000
Q1 2023 Apr 17, 2023	BUY	$46.97 - $58.27 $5,307 - $6,584	113 Added 54.59%	320 $15,000
Q4 2022 Jan 30, 2023	BUY	$52.05 - $65.0 $10,774 - $13,455	207 New	207 $12,000

190

42.9M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $661M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Byrne Asset Management LLC with notifications on news.